Patent details
LUC50004
Product Name:
daratumumab, bortezomib, lenalidomide and dexamethasone
Basic Information
- Publication number:
- LUC50004
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
-
EP078178167
- Legal Status:
- Pending & Published
- Application number:
- LUC50004
- First applicant's nationality:
- Procedural language:
- English
Marketing Authorization
- Marketing Authorization Number:
- EU/1/16/1101
- Marketing Authorization Type:
-
- Marketing Authorization Date:
- 21/10/2024
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 15/04/2025
- First Marketing Authorization date:
- 21/10/2024
- Grant date:
- Activation date:
- Publication date:
- 18/04/2025
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 26/09/2032
- SPC Extension Expiration:
- 26/09/2032
- Rejection date:
- Withdrawal date:
Owner
- From:
- 15/04/2025
-
-
- Name:
- GENMAB A/S
- Address:
- Carl Jacobsens Vej 30, DK-2500, Valby, Denmark (DK)
Agent
- Name:
- Dennemeyer & Associates S.A.
- From:
- 15/04/2025
- Address:
- 55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
- To:
Publication
Bulletin
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2025/06
- Publication date:
- 12/05/2025
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
Annual Fees
- Annual Fee Due Date:
- 30/09/2027
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
-
- Last Annual Fee Payment Date:
-
- Last Annual Fee Paid Number:
-
- Payer:
-